* Adaptive Biotechnologies Corp ADPT.OQ ADPT.O is
expected
to show a fall in quarterly revenue when it reports results on
May 3.
* The Seattle Washington-based company is expected to
report a
4.7% decrease in revenue to $36.811 million from $38.62 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Adaptive
Biotechnologies
Corp is for a loss of 38 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.
* Wall Street's median 12-month price target for Adaptive
Biotechnologies Corp is $12, above its last closing price
of $7.35.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.34 -0.35 -0.28 Beat 19.2
Sep. 30 2022 -0.37 -0.38 -0.32 Beat 14.9
Jun. 30 2022 -0.41 -0.43 -0.37 Beat 14
Mar. 31 2022 -0.45 -0.46 -0.44 Beat 4.1
Dec. -0.47 -0.45 -0.43 Beat 4.7
31 2021
Sep. 30 2021 -0.42 -0.42 -0.40 Beat 5
Jun. 30 2021 -0.42 -0.43 -0.35 Beat 18.1
Mar. 31 2021 -0.41 -0.41 -0.29 Beat 29
This summary was machine generated May 2 at 02:03 GMT. All
figures in US dollars unless otherwise stated